Happe Spine expects to receive FDA clearance within the next two to three months for its new porous, bioactive material that encourages bone growth, according to the report.
After FDA review, Happe plans to target hospitals, ASCs and orthopedic practices.
Last year, Happe closed on a $3.35 million series A funding round, and an additional $2 million round this year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
